Feasibility of a Randomized, Interventional Pilot Clinical Study of Oral Cannabinoids in People with HIV on Antiretroviral Therapy: CTNPT 028
Authors:
- Ralph-Sydney Mboumba BouassaRBRalph-Sydney Mboumba Bouassa
- Judy NeedhamJNJudy Needham
- Dana NohynekDNDana Nohynek
- Suzanne SamaraniSSSuzanne Samarani
- Florian BobeufFBFlorian Bobeuf
- Lina Del BalsoLBLina Del Balso
- Natalie PaisibleNPNatalie Paisible
- Claude VertzagiasCVClaude Vertzagias
- Giada SebastianiGiada Sebastiani
- Shari MargoleseSMShari Margolese
- Enrico MandarinoEMEnrico Mandarino
- Joel SingerJSJoel Singer
Open Access
- 13 July 2024
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (7) , 745
Abstract
Cannabis-based medicines (CBMs) could help reduce systemic inflammation in people with HIV (PWH). In a prospective, randomized pilot study we enrolled participants from August 2021–April 2022 with HIV, aged ≥18 and on antiretroviral therapy and randomly assigned them to cannabidiol (CBD) ± Δ9-tetrahydrocannabinol (THC) capsules for 12 weeks with the primary objective being to assess safety and tolerability. Here we report on timeliness to study initiation, enrolment, compliance and retention rates. The target sample size was not reached. Two hundred and five individuals were approached, and 10 consented and were randomized; the rest refused (reasons: cannabis-related stigma/discomfort; too many study visits/insufficient time; unwillingness to undergo a “washout period” for three weeks) or were not eligible. The age of those randomized was 58 years (IQR 55–62); 80% were male. Only three met all criteria (30% enrolment compliance); seven were enrolled with minor protocol deviations. Compliance was excellent (100%). Eight (80%) participants completed the study; two (20%) were withdrawn for safety reasons (transaminitis and aggravation of pre-existing anemia). Time to study initiation and recruitment were the most challenging aspects. Ongoing work is required to reduce stigma related to CBMs. Future studies should find a balance between the requirements for safety monitoring and frequency of study visits.Keywords
Funding Information
- Canadian Institutes of Health Research (CC1-177334, CTNPT 028, #296306)
- CIHR Canadian HIV Trials Network (CC1-177334, CTNPT 028, #296306)
- Lotte & John Hecht Memorial Foundation (CC1-177334, CTNPT 028, #296306)
- CIHR postdoctoral fellowship (CC1-177334, CTNPT 028, #296306)
- FRSQ-S Chercheur Boursier Clinicien Senior career award (CC1-177334, CTNPT 028, #296306)
- FRQ-S Junior 2 Chercheur Boursier Clinicien career award (CC1-177334, CTNPT 028, #296306)
This publication has 56 references indexed in Scilit:
- Cannabidiol Compared to Pharmacological Treatment as Usual for Crack Use Disorder: A Feasibility, Preliminary Efficacy, Parallel, Double-Blind, Randomized Clinical TrialInternational Journal of Mental Health and Addiction, 2024
- Inflammaging and CannabinoidsAgeing Research Reviews, 2021
- A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfactionSupportive Care in Cancer, 2021
- A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effectsEuropean Archives of Psychiatry and Clinical Neuroscience, 2019
- Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility StudyJournal of Autism and Developmental Disorders, 2018
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy SubjectsCNS Drugs, 2018
- Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A reviewContemporary Clinical Trials Communications, 2018
- Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionDrugs, 2016
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007